|
Professor David Collingridge: Editor-in-Chief, The Lancet Oncology & Publishing Director, The Lancet Specialty Journals; 125 London Wall, London, EC2Y 5AS, United Kingdom Writing a manuscript to survive the demanding selection and peer-review processes of high-impact oncology journals can sometimes seem shrouded in a veil of mystery and a daunting prospect. Many top-end journals have specific writing requirements, detailed submission needs, and a stringent focus on novelty and rigour. Together, these factors help high-end journals publish papers that have a strong possibility of substantially influencing thinking or directly affecting clinical practice, which in turn ensures readers can have confidence in the veracity of the publication and authors can take satisfaction from being among a rarified group of researchers that have published content in the in the top 5% of the medical literature. In my presentation, I will aim to uncover some the mysteries surrounding these factors by discussing how to write a good manuscript, the use of reporting standards, conflicts of interests, the difference between authors and contributors, what journals typically look for in an article, and perhaps most importantly, how editors judge papers at submission and during peer review. The talk will also highlight the evolution on publishing in recent times, the culture at The Lancet Group, the peer review processes at The Lancet's family of journals, and the interplay between our various publications. Armed with these insights, prospective authors will hopefully have more tools at their disposal to achieve greater publishing success. |
|
|
